Santarus to Present SAN-300 Phase I Data at 2013 American College of Rheumatology
October 25, 2013 at 07:04 AM EDT
Santarus (NASDAQ: SNTS ) today announced that data from its Phase I clinical study with its investigational drug SAN-300, a novel antibody that inhibits very late antigen-1 (VLA-1; α1β1 integrin), will be
